Payment overview · 2025
General Payments
$268.90
3 reported records · 3 companies
Healthcare provider profile · identity verified
Ngoc An Phan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PHILADELPHIA, PA · NPI 1346246998
Verified facts
What the public records show
CMS Open Payments records show Ngoc An Phan, M.D. received $268.90 in general payments during 2025 across 3 reported records.
Gilead Sciences, Inc. accounted for 46.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 304 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $126.00 | 46.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $119.04 | 44.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.86 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $268.90 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $119.04 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.86 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
219 | 48 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
304 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
92 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Azelastine Hcl | Azelastine Hcl | 703 | 188 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 620 | 157 |
| Montelukast Sodium | Montelukast Sodium | 577 | 151 |
| Atorvastatin Calcium | Atorvastatin Calcium | 571 | 155 |
| Ezetimibe | Ezetimibe | 503 | 130 |
| Calcium Acetate | Calcium Acetate | 488 | 118 |
| Rabeprazole Sodium | Rabeprazole Sodium | 464 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 459 | 125 |
| Desloratadine | Desloratadine | 426 | 132 |
| Lidocaine | Lidocaine | 384 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 378 | 118 |
| Vascepa | Icosapent Ethyl | 306 | 53 |
| Jardiance | Empagliflozin | 304 | 67 |
| Celecoxib | Celecoxib | 278 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 248 | 72 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 248 | 151 |
| Ammonium Lactate | Ammonium Lactate | 247 | 90 |
| Gabapentin | Gabapentin | 245 | 63 |
| Metformin Hcl | Metformin Hcl | 239 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 239 | 64 |
| Nebivolol Hcl | Nebivolol Hcl | 239 | 57 |
| Diclofenac Sodium | Diclofenac Sodium | 238 | 54 |
| Farxiga | Dapagliflozin Propanediol | 219 | 48 |
| Pioglitazone Hcl | Pioglitazone Hcl | 206 | 59 |
| Famotidine | Famotidine | 197 | 57 |
| Prolia | Denosumab | 197 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 192 | 51 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 183 | 48 |
| Procto-Med Hc | Hydrocortisone | 181 | 32 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 168 | 58 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 163 | 32 |
| Valsartan | Valsartan | 163 | 43 |
| Dexlansoprazole Dr | Dexlansoprazole | 149 | 67 |
| Mupirocin | Mupirocin | 142 | 70 |
| Raloxifene Hcl | Raloxifene Hcl | 142 | 37 |
| Azithromycin | Azithromycin | 140 | 100 |
| Ibandronate Sodium | Ibandronate Sodium | 134 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 132 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 36 |
| Loperamide | Loperamide Hcl | 124 | 74 |
| Baclofen | Baclofen | 122 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 34 |
| Allopurinol | Allopurinol | 116 | 31 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 111 | 48 |
| Alendronate Sodium | Alendronate Sodium | 108 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 98 | 25 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 97 | 19 |
| Mirtazapine | Mirtazapine | 97 | 30 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 96 | 34 |
| Irbesartan | Irbesartan | 96 | 31 |
| Linzess | Linaclotide | 96 | 24 |
| Kerendia | Finerenone | 95 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 34 |
| Trulicity | Dulaglutide | 92 | 18 |
| Losartan Potassium | Losartan Potassium | 89 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 86 | 40 |
| Myrbetriq | Mirabegron | 85 | 15 |
| Omeprazole | Omeprazole | 81 | 35 |
| Entecavir | Entecavir | 80 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 31 |
| Eliquis | Apixaban | 73 | 16 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 69 | 19 |
| Gemtesa | Vibegron | 67 | 14 |
| Dutasteride | Dutasteride | 66 | 13 |
| Tradjenta | Linagliptin | 65 | 18 |
| Finasteride | Finasteride | 63 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 50 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 61 | 29 |
| Fenofibrate | Fenofibrate | 60 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 56 | 22 |
| Colchicine | Colchicine | 55 | 18 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 54 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 54 | 16 |
| Carvedilol | Carvedilol | 53 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 16 |
| Selenium Sulfide | Selenium Sulfide | 51 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 51 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 50 | 12 |
| Ozempic | Semaglutide | 50 | suppressed |
| Spironolactone | Spironolactone | 50 | 18 |
| Diltiazem 24hr Er | Diltiazem Hcl | 49 | 15 |
| Lansoprazole | Lansoprazole | 49 | 23 |
| Nifedipine Er | Nifedipine | 48 | 14 |
| Erythromycin | Erythromycin Base | 44 | 18 |
| Indapamide | Indapamide | 44 | 20 |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 44 | 17 |
| Glipizide | Glipizide | 42 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 40 | suppressed |
| Rybelsus | Semaglutide | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 36 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 35 | 11 |
| Amoxicillin | Amoxicillin | 34 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 27 |
| Prednisone | Prednisone | 26 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 24 | 24 |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Furosemide | Furosemide | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Cyclosporine Modified | Cyclosporine, Modified | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $268.90 · 3 records | Gilead Sciences, Inc. | AIRSUPRA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error